Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?

Berntorp, Erik LU (2003) In Haematologica 88(6). p.3-3
Abstract
Factor VIII inhibitors may interfere with several important functional binding sites on the factor VIII molecule including that of von Willebrand factor, which binds to the C2 domain. There are in vitro and in vivo observations that inhibitors reacting against the factor VIII light-chain C2 domain may display a lower inhibitor titer against von Willebrand factor containing concentrates as compared to pure products. In low titer inhibitor patients it can be anticipated that von Willebrand factor containing concentrates give a better hemostatic effect. The role in immune tolerance induction is of great interest as an increased success rate and decreased treatment time may have a substantial impact on the cost of treatment. Case reports and... (More)
Factor VIII inhibitors may interfere with several important functional binding sites on the factor VIII molecule including that of von Willebrand factor, which binds to the C2 domain. There are in vitro and in vivo observations that inhibitors reacting against the factor VIII light-chain C2 domain may display a lower inhibitor titer against von Willebrand factor containing concentrates as compared to pure products. In low titer inhibitor patients it can be anticipated that von Willebrand factor containing concentrates give a better hemostatic effect. The role in immune tolerance induction is of great interest as an increased success rate and decreased treatment time may have a substantial impact on the cost of treatment. Case reports and treatment experience from some centers indicate a better success rate with von Willebrand factor containing concentrates. Even if formal, well-controlled studies are needed, it can already be recommended that inhibitor plasma should be tested against a panel of concentrates in order to select the less neutralized concentrate for use in inhibitor patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haematologica
volume
88
issue
6
pages
3 - 3
publisher
Ferrata Storti Foundation
external identifiers
  • pmid:12826529
ISSN
1592-8721
language
English
LU publication?
yes
id
ebdc959f-d3cf-45ce-b086-e3f22350e814 (old id 1127038)
date added to LUP
2016-04-01 15:48:53
date last changed
2018-11-21 20:36:34
@article{ebdc959f-d3cf-45ce-b086-e3f22350e814,
  abstract     = {{Factor VIII inhibitors may interfere with several important functional binding sites on the factor VIII molecule including that of von Willebrand factor, which binds to the C2 domain. There are in vitro and in vivo observations that inhibitors reacting against the factor VIII light-chain C2 domain may display a lower inhibitor titer against von Willebrand factor containing concentrates as compared to pure products. In low titer inhibitor patients it can be anticipated that von Willebrand factor containing concentrates give a better hemostatic effect. The role in immune tolerance induction is of great interest as an increased success rate and decreased treatment time may have a substantial impact on the cost of treatment. Case reports and treatment experience from some centers indicate a better success rate with von Willebrand factor containing concentrates. Even if formal, well-controlled studies are needed, it can already be recommended that inhibitor plasma should be tested against a panel of concentrates in order to select the less neutralized concentrate for use in inhibitor patients.}},
  author       = {{Berntorp, Erik}},
  issn         = {{1592-8721}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{3--3}},
  publisher    = {{Ferrata Storti Foundation}},
  series       = {{Haematologica}},
  title        = {{Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?}},
  volume       = {{88}},
  year         = {{2003}},
}